Essential Premium

Renaissance’s Public Funds Stage Double-Digit Comeback in November

After a bruising October, the quant giant’s RIEF and RIDA funds roared back with gains of more than 12 percent, though both remain below September levels.

Ex-TCI Partner Edgar Allen’s High Ground Racks Up Record Year

The Europe-focused long-short equity fund is up nearly 35 percent in 2025, marking its strongest performance since inception.

Sponsored

The Historical Benefits of US Private Real Estate

Biopharma Funds Deliver Market-Beating Returns as Valuations Snap Back

With blockbuster gains in 2025 and Wall Street asserting that investors overreacted to government cuts at the FDA, hedge funds focused on life sciences are emerging as some of the industry’s biggest winners.

Related Content

A Jim Simons Market Mystery — Solved?

Richard Teitelbaum

Does Jim Simons Have the Zuckerman Curse?

Michelle Celarier

Hedge Funds Legends Quietly Contacting Investors, Citing Historic Buying Opportunity

Leanna Orr

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram